US HB4215 | 2017-2018 | 115th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on November 1 2017 - 25% progression, died in committee
Action: 2017-11-01 - Referred to the House Committee on Ways and Means.
Pending: House Ways And Means Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on November 1 2017 - 25% progression, died in committee
Action: 2017-11-01 - Referred to the House Committee on Ways and Means.
Pending: House Ways And Means Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes. This bill requires the Centers for Medicare & Medicaid Services to pay, to a provider that furnishes a hematopoietic stem cell transplant, an adjusted Medicare payment consistent with the Medicare payment methodology for kidney-acquisition costs outlined in regulation. Under the applicable regulation, kidney-acquisition costs are treated apart from the prospective payment rate for inpatient operating costs, and payment is adjusted to compensate the hospital for certain reasonable expenses. "Hematopoietic stem cell transplant" means the infusion of allogeneic hematopoietic cells (including bone marrow, peripheral blood stem cells, and cord-blood units, but excluding embryonic stem cells) that are: (1) not more than minimally manipulated; and (2) intended to reestablish hematopoietic function in an individual whose blood marrow or immune system is damaged, defective, or adversely affective by a congenital disorder.
Title
To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes.
Sponsors
Rep. Erik Paulsen [R-MN] | Rep. Ron Kind [D-WI] | Rep. Doris Matsui [D-CA] | Rep. Gus Bilirakis [R-FL] |
Rep. Earl Blumenauer [D-OR] | Rep. Betty McCollum [D-MN] | Rep. Collin Peterson [D-MN] | Rep. Lynn Jenkins [R-KS] |
Sen. Roger Marshall [R-KS] | Rep. Zoe Lofgren [D-CA] | Rep. Christopher Smith [R-NJ] | Rep. Joyce Beatty [D-OH] |
Rep. John Lewis [D-GA] | Rep. Richard Hudson [R-NC] | Rep. Dennis Ross [R-FL] | Rep. Thomas Rooney [R-FL] |
Rep. Salud Carbajal [D-CA] | Rep. Patrick Meehan [R-PA] | Rep. Carol Shea-Porter [D-NH] | Rep. Ro Khanna [D-CA] |
Rep. Tom Emmer [R-MN] | Rep. Mike Thompson [D-CA] | Rep. Charlie Crist [D-FL] | Rep. Peter DeFazio [D-OR] |
Rep. Kenny Marchant [R-TX] | Rep. Peter Roskam [R-IL] | Rep. Elizabeth Esty [D-CT] |
History
Date | Chamber | Action |
---|---|---|
2017-11-01 | House | Referred to the House Committee on Ways and Means. |
2017-11-01 | House | Introduced in House |
Subjects
Blood and blood diseases
Cancer
Cell biology and embryology
Health
Hospital care
Immunology and vaccination
Medicare
Organ and tissue donation and transplantation
Cancer
Cell biology and embryology
Health
Hospital care
Immunology and vaccination
Medicare
Organ and tissue donation and transplantation
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/115th-congress/house-bill/4215/all-info |
Text | https://www.congress.gov/115/bills/hr4215/BILLS-115hr4215ih.pdf |